# PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

> **NCT06156878** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 41 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** Anti-EGFR and PD-1 inhibitor arm

## Key facts

- **NCT ID:** NCT06156878
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2025-08
- **Final completion:** 2025-08
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2023-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06156878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06156878, "PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06156878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*